Genomic Landscape of Pulmonary Sarcomatoid Carcinoma
Cancer Research and Treatment · 2024
DOI: 10.4143/crt.2023.764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Hyun Jung Kwon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Pulmonary sarcomatoid carcinoma (PSC) is a rare aggressive subtype of non–small cell lung cancer (NSCLC) with limited therapeutic strategies. We attempted to elucidate the evolutionary trajectories of PSC using multiregional and longitudinal tumor samples.Materials and Methods A total of 31 patients were enrolled in this study and 11 longitudinal samples were available from them. Using whole exome sequencing data, we analyzed the mutational signatures in both carcinomatous and sarcomatous areas in primary tumors of the 31 patients and longitudinal samples obtained from 11 patients. Furthermore, digital droplet polymerase chain reaction (ddPCR), and programmed death-ligand 1 (PD-L1) immunohistochemistry using the Ventana SP263 assay were performed.
Results
TP53 was identified as the most frequently altered gene in the primary (74%) and metastatic (73%) samples. MET exon 14 skipping mutations, confirmed by ddPCR, and TP53 mutations were mutually exclusive; whereas, MET exon 14 skipping mutations frequently co-occurred with MDM2 amplification. Metastatic tumors showed dissimilar genetic profiles from either primary component. During metastasis, the signatures of APOBEC decreased in metastatic lesions compared with that in primary lesions. PSC showed higher MET and KEAP1 mutations and stronger PD-L1 protein expression compared with that recorded in other NSCLCs.
Conclusion
Decreased APOBEC signatures and subclonal diversity were detected during malignant progression in PSC. Frequent MET mutations and strong PD-L1 expression distinguished PSC from other NSCLCs. The aggressiveness and therapeutic difficulties of PSC were possibly attributable to profound intratumoral and intertumoral genetic diversity. Next-generation sequencing could suggest the appropriate treatment strategy for PSC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
- Department of Pathology and Translational Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- Artificial Intelligence Institute of Seoul National University, Seoul, Korea.
- Genomic Medicine Institute, Seoul National University Medical Research Center, Seoul, Korea.
Zitieren
APA
Kwon, H. J., Lee, S., Han, Y. B., Lee, J., Kwon, S., Kim, H., & Chung, J. H. (2024). Genomic Landscape of Pulmonary Sarcomatoid Carcinoma. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.764
Vancouver
Kwon HJ, Lee S, Han YB, Lee J, Kwon S, Kim H, et al. Genomic Landscape of Pulmonary Sarcomatoid Carcinoma. Cancer Research and Treatment. 2024. doi:10.4143/crt.2023.764
BibTeX
@article{Kwon2024,
author = {Kwon, Hyun Jung and Lee, Sejoon and Han, Yeon Bi and Lee, Jeonghyo and Kwon, Soohyeon and Kim, Hyojin and Chung, Jin-Haeng},
title = {Genomic Landscape of Pulmonary Sarcomatoid Carcinoma},
journal = {Cancer Research and Treatment},
year = {2024},
doi = {10.4143/crt.2023.764}
}
EUVIMED